A detailed history of Mariner, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mariner, LLC holds 12,283 shares of PTGX stock, worth $563,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,283
Previous 12,724 3.47%
Holding current value
$563,052
Previous $368,000 15.49%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$24.66 - $34.8 $10,875 - $15,346
-441 Reduced 3.47%
12,283 $425,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $75,611 - $111,560
3,470 Added 37.5%
12,724 $368,000
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $74,296 - $123,950
-5,288 Reduced 36.36%
9,254 $212,000
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $61,849 - $87,731
3,708 Added 34.23%
14,542 $242,000
Q2 2023

Aug 11, 2023

SELL
$18.02 - $29.36 $58,348 - $95,067
-3,238 Reduced 23.01%
10,834 $299,000
Q1 2023

May 12, 2023

BUY
$10.78 - $25.38 $36,899 - $86,875
3,423 Added 32.14%
14,072 $324,000
Q4 2022

Feb 14, 2023

SELL
$7.36 - $11.17 $18,090 - $27,455
-2,458 Reduced 18.75%
10,649 $116,000
Q3 2022

Nov 10, 2022

BUY
$7.86 - $11.71 $103,021 - $153,482
13,107 New
13,107 $110,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.